Human umbilical vein endothelial cell vaccine therapy in patients with recurrent glioblastoma

Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma

(2011) Olivier Keunen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis

(2010) Tao Xu et al.   BMC CANCER

Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma

(2010) Tracy T. Batchelor et al.   JOURNAL OF CLINICAL ONCOLOGY

FDA accelerated approval benefits glioblastoma

(2010) Timothy Cloughesy   LANCET ONCOLOGY

Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells

(2010) Lucia Ricci-Vitiani et al.   NATURE

Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors

(2010) B. J. Scott et al.   NEURO-ONCOLOGY

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL

Mediators of Glioblastoma Resistance and Invasion during Antivascular Endothelial Growth Factor Therapy

(2009) A. K. Lucio-Eterovic et al.   CLINICAL CANCER RESEARCH

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy

(2008) Yurai Okaji et al.   EUROPEAN JOURNAL OF CANCER

Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme

(2008) Shuichi Izumoto et al.   JOURNAL OF NEUROSURGERY